Security
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares · CANF
CANFNYSE_AMERICANotherCurrentCIK 1536196Updated Oct 27, 2026
CANF price & chart
Loading TradingView…
AMEX:CANF on TradingView ↗About the company
We are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.
In the news
Wall Street is Watching These Biotechs ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,720,000Source | 5,922,000Source | 11,032,000Source | 14,746,000Source | 9,680,000Source | 12,800,000Source | 13,667,000Source | 10,984,000Source | 9,514,000Source | 9,120,000Source | 9,989,000Source | 9,283,000Source |
| Property, Plant and Equipment, NetUSD | 5,000Source | 32,000Source | 36,000Source | 46,000Source | 50,000Source | 30,000Source | — | — | 5,000Source | 27,000Source | 29,000Source | 42,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,454,000Source | 4,719,000Source | — | — | 7,537,000Source | 9,059,000Source | 8,202,000Source | — | 5,528,000Source | 4,825,000Source | 4,278,000Source | 2,978,000Source |
| Accounts Receivable | — | — | — | — | — | — | — | — | — | —Source | — | — |
| Assets, CurrentUSD | 7,624,000Source | 5,828,000Source | 10,909,000Source | 14,589,000Source | 9,553,000Source | 12,704,000Source | — | — | 9,440,000Source | 8,982,000Source | 9,908,000Source | 9,157,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,168,000Source | 1,100,000Source | 1,293,000Source | 1,823,000Source | 1,745,000Source | — | — | — | 900,000Source | 1,095,000Source | 986,000Source | 1,170,000Source |
| Operating Lease, Right-of-Use AssetUSD | 91,000Source | 62,000Source | 87,000Source | 111,000Source | 77,000Source | 66,000Source | — | — | 69,000Source | 111,000Source | 52,000Source | 84,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | — | 163,790,000Source | 160,814,000Source | 93,410,000Source | 96,386,000Source | 98,056,000Source | — | — | — | — | 163,597,000Source | 154,192,000Source |
| Retained Earnings (Accumulated Deficit)USD | -171,237,000Source | -162,438,000Source | -155,067,000Source | -145,299,000Source | -130,566,000Source | -119,261,000Source | — | — | -176,189,000Source | -166,361,000Source | -158,481,000Source | -150,847,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,127,000Source | 1,127,000Source | 1,127,000Source | 1,127,000Source | 1,127,000Source | 1,127,000Source | — | — | 1,127,000Source | 1,127,000Source | 1,127,000Source | 1,127,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,184,000Source | 2,479,000Source | 6,874,000Source | 9,892,000Source | 3,955,000Source | 9,156,000Source | — | — | 5,592,000Source | 5,436,000Source | 6,243,000Source | 4,472,000Source |
| Additional Paid in Capital, Common StockUSD | 174,294,000Source | — | — | — | — | — | — | — | 180,654,000Source | 170,670,000Source | — | 500Source |
| Liabilities and EquityUSD | 7,720,000Source | 5,922,000Source | 11,032,000Source | 14,746,000Source | 9,680,000Source | 12,800,000Source | — | — | 9,514,000Source | 9,120,000Source | 9,989,000Source | 9,283,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,120,000Source | 1,987,000Source | 2,233,000Source | 2,153,000Source | 2,359,000Source | 1,501,000Source | — | — | 2,731,000Source | 2,052,000Source | 2,020,000Source | 2,502,000Source |
| Operating Lease, Liability, CurrentUSD | 57,000Source | 36,000Source | 44,000Source | 47,000Source | 43,000Source | 36,000Source | — | — | 56,000Source | 53,000Source | 27,000Source | 48,000Source |
| Operating Lease, Liability, NoncurrentUSD | 33,000Source | 21,000Source | 22,000Source | 40,000Source | 25,000Source | 22,000Source | — | — | 15,000Source | 51,000Source | 13,000Source | 14,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | 301,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | 7,882,000Source | 8,903,000Source | — |
| Deferred Revenue, CurrentUSD | — | — | 783,000Source | 818,000Source | 1,002,000Source | — | — | — | — | — | — | 783,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 1,903,000Source | 2,661,000Source | 3,341,000Source | 2,121,000Source | — | — | — | — | — | 2,295,000Source |
| Short-term InvestmentsUSD | 2,000Source | 9,000Source | — | — | — | — | — | — | 1,000Source | 5,000Source | 19,000Source | 8,000Source |
| Common Stock, Value, Issued | — | — | — | —Source | —Source | —Source | — | — | — | — | — | — |
| IssuedCapital | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| TradeAndOtherCurrentPayables | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | 24,000Source | — | — | 14,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 340,000Source | 362,000Source | 261,000Source | 263,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -8,949,000Source | -7,637,000Source | -8,440,000Source | -10,801,000Source |
| Cash flows from investing activities: | |||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -2,000Source | 1,495,000Source | 498,000Source | 9,502,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | 2,000Source | 5,000Source | 2,000Source | 9,000Source |
| Cash flows from financing activities: | |||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 9,644,000Source | 6,711,000Source | 9,144,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | 703,000Source | 547,000Source | 1,300,000Source | -1,412,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,454,000Source | 4,719,000Source | 3,458,000Source | 1,712,000Source | 7,537,000Source | 5,528,000Source | 4,825,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | 10,000Source | -22,000Source | 98,000Source | -113,000Source |
| Additional Financial Items | |||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | 340,000Source | 362,000Source | 261,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | 7,882,000Source | 8,903,000Source | — |
| DepreciationUSD | — | — | — | — | — | 24,000Source | 7,000Source | 15,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | 3,662,000Source | 3,047,000Source | 2,955,000Source | 3,143,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | 284,000Source | -291,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | 122,000Source | 250,000Source | 561,000Source | -77,000Source |
| Operating ExpensesUSD | — | — | — | — | — | 10,355,000Source | 8,804,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 561,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | 2,933,000Source | 2,223,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 743,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 405,000Source | 674,000Source | — | 810,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 263,000Source |
| Operating Income (Loss)USD | -9,950,000Source | -8,130,000Source | -8,195,000Source | -10,096,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 561,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Net Income (Loss) Attributable to ParentUSD | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Earnings Per Share, BasicUSD per share | -5.97Source | 0Source | -0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | -5.97Source | 0Source | -0.01Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,646,208Source | 2,175,926,512Source | 1,278,333,912Source | 815,746,293Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,646,208Source | 2,175,926,512Source | 1,278,333,912Source | 815,746,293Source |
| Interest Expense (non-operating)USD | 284,000Source | -291,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 3,662,000Source | 3,047,000Source | 2,955,000Source | 3,143,000Source |
| Interest Income (Expense), NetUSD | — | — | — | -77,000Source |
| Investment Income, NetUSD | 122,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 122,000Source | 250,000Source | 561,000Source | -77,000Source |
| Operating ExpensesUSD | 10,355,000Source | 8,804,000Source | — | — |
| Other General and Administrative ExpenseUSD | — | — | — | 126,000Source |
| Research and Development ExpenseUSD | 6,693,000Source | 5,757,000Source | 5,983,000Source | 7,763,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 743,000Source | — |
Offerings
Registration 333-298625
Registration 333-269485
Registration 333-294760
Registration 333-288890
- Gross proceeds
- 4992916.47
- Net proceeds
- 4642916.48
- Deal price
- 0.6
- Shares
- 8321527
- Offering price
- $0.60
- Ticker
- CANF
Filing attachments
ea030962301ex99-1.htm · 6-K · 2026-10-26
Exhibit 99.1 Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months RAMAT GAN, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology compan…
Read attachment ↗ea030493901ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeli…
Read attachment ↗ea030436701ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K and our Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”). Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accountin…
Read attachment ↗ea030436701ex99-2.htm · 6-K · 2026-09-08
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED IN U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Operating Loss 4 Condensed Consolidated Statements of Changes in Shareholders’ Equity 5 Conden…
Read attachment ↗ea030438301ex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding wa…
Read attachment ↗ea030420101ex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, …
Read attachment ↗